How Do the Renal Data From CREDENCE and CARMELINA Compare? How Do the Renal Data From CREDENCE and CARMELINA Compare?

Meg Jardine and Christoph Wanner, investigators from the CREDENCE and CARMELINA trials, respectively, discuss the implications for SGLT2 inhibitor and DPP-4 inhibitor use in patients with kidney disease.Medscape Diabetes & Endocrinology
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news